Shandong Keyuan Pharmaceutical Co. Ltd. A Total Assets
Shandong Keyuan Pharmaceutical Co. Ltd. A total assets. Based on the latest financial reports, Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) holds total assets worth CN¥1.60 Billion CNY (≈ $234.77 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shandong Keyuan Pharmaceutical Co. Ltd. (301281) total market value for the company's overall valuation and market capitalisation.
Total Assets of Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
Total assets of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024. This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See Shandong Keyuan Pharmaceutical Co. Ltd. (301281) stock price for real-time trading data and today's change.
Shandong Keyuan Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Shandong Keyuan Pharmaceutical Co. Ltd. A Total Assets Breakdown (December 2024)
Shandong Keyuan Pharmaceutical Co. Ltd. A total assets breakdown as of December 2024. Shandong Keyuan Pharmaceutical Co. Ltd. A's total assets of CN¥1.60 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.5% |
| Accounts Receivable | CN¥53.61 Million | 3.5% |
| Inventory | CN¥128.94 Million | 8.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥108.98 Million | 7.0% |
| Goodwill | CN¥1.82 Million | 0.1% |
Asset Composition Trend (2021–2024)
This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 301281 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Keyuan Pharmaceutical Co. Ltd. A's current assets represent 44.5% of total assets in 2024, an increase from 36.4% in 2021.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 11.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 9.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 8.3% of total assets.
Shandong Keyuan Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Shandong Keyuan Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Shandong Keyuan Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.55 | 6.72 | 6.72 |
| Quick Ratio | 5.08 | 5.77 | 5.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥555.85 Million | CN¥604.82 Million | CN¥604.82 Million |
Shandong Keyuan Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shandong Keyuan Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.96 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | CN¥1.55 Billion |
| Market Capitalization | $629.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Keyuan Pharmaceutical Co. Ltd. A's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Keyuan Pharmaceutical Co. Ltd. A's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total assets of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion ≈ $227.18 Million |
+5.61% |
| 2023-12-31 | CN¥1.47 Billion ≈ $215.10 Million |
+125.53% |
| 2022-12-31 | CN¥651.79 Million ≈ $95.38 Million |
+16.49% |
| 2021-12-31 | CN¥559.51 Million ≈ $81.87 Million |
-- |
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more